

# **Engaging Participants in Precision Clinical Trials: Examples from Alzheimer's Disease Prevention Trials**

Jessica B. Langbaum, PhD
Principal Scientist, Banner Alzheimer's Institute
Associate Director, Alzheimer's Prevention Initiative



#### **Example of a Successful Recruitment Mechanism: Colombian Alzheimer's Prevention Registry**

- Launched in anticipation of Alzheimer's prevention clinical trials, serving as a pre-enrollment recruitment mechanism to identify potential study participants
- To date, enrolled >5600 PSEN1 E280A mutation kindred members in Colombia
  - 1173 mutation carriers
  - o 4420 kindred non-carriers
  - Required considerable community outreach, review of church records, family meetings, and other outreach tactics
- All participants for the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial were recruited from the Registry.

## Example of a Successful Recruitment Mechanism: GeneMatch

- Launched in November 2015 as an online, trial-independent genetic recruitment registry for Alzheimer's prevention trials in the US
  - o www.endALZnow.org/genematch
- Participants are not told their APOE test results, but recruiting studies may require disclosure as part of screening/enrollment
  - Testing done by a CLIA certified / CAP accredited lab
- To date, enrolled >33,000 cognitively healthy adults ages 55-75
  - ~4% APOE ε4/ε4
  - ~30% APOE ε3/ε4
  - Required significant advertising, community outreach and talks
- Continued email engagement with participants is important since it may be months to years until they are matched to a trial
- Primary recruitment source in the US for the API Generation Study



#### **Example of Recruitment Funnel for the API Generation Study**



Genotyping (e.g. GeneMatch)

> (~100k-120k estimated)

Known HMs Consenting for clinical study

> Elgibility Criteria

Randomized (~600) Estimated that 100k-120k
GeneMatch completions are needed
to randomize approxminately 600
patients in the US.

Participants in age range are still active and may not have time to dedicate to a clinical trial

Targeted population (APOE4 Homozygotes) are limited; Eligible participants can fail on cognitive assessments





## **Thank you**

